--- title: "Weekly Recap | Natera +0.59%, closing in on record highs" type: "News" locale: "en" url: "https://longbridge.com/en/news/298100952.md" description: "Natera (NTRA) rose 0.59% this week to close at $328.18, while the S&P 500 gained 0.09%, leaving the stock about 0.5 percentage points ahead of the benchmark. Weekly amplitude was 4.99%, with total volume of 5.25m shares. Daily average volume came in around 1.05m, roughly 15.7% below the median, so trading leaned quiet. The stock opened Monday at a low of $316, recovered through Wednesday to $330." datetime: "2026-09-05T07:41:50.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/298100952.md) - [en](https://longbridge.com/en/news/298100952.md) - [zh-HK](https://longbridge.com/zh-HK/news/298100952.md) generator: "portal-rs" --- # Weekly Recap | Natera +0.59%, closing in on record highs ## The Week Natera (NTRA) rose 0.59% this week to close at $328.18, while the S&P 500 gained 0.09%, leaving the stock about 0.5 percentage points ahead of the benchmark. Weekly amplitude was 4.99%, with total volume of 5.25m shares. Daily average volume came in around 1.05m, roughly 15.7% below the median, so trading leaned quiet. The stock opened Monday at a low of $316, recovered through Wednesday to $330.92, hit a weekly high of $332 on Thursday, and then consolidated near the upper end of the range into Friday. ## Key Events The most company-specific development arrived Tuesday: a new publication established strong clinical validation for Signatera™ in minimal residual disease (MRD) assessment for lymphoma, directly relevant to Natera’s core oncology testing franchise. The same day, two broader financial media pieces mentioned Natera in passing — one a multi-industry market overview and the other a look at business models outside traditional sector groupings. After Friday’s close, CEO Steven Leonard Chapman disposed of 1,698 common shares for about $545,441, a small-scale insider sale. A Saturday article reviewed ten-year returns from owning Natera stock, a retrospective piece with no new information this week. ## Analyst Ratings As of 3 September 2026, 22 institutions cover Natera: 14 rate it buy, 5 overweight, and 3 hold, with no underweight or sell ratings. The consensus recommendation is buy, and the consensus target price is $338.07, about 3.01% above this week’s close of $328.18. The target range spans $280 to $376, a wide gap that shows disagreement among analysts on valuation. Natera ranks 19th out of 507 biotech companies in analyst rating performance, placing it near the top of its industry. ## The Week Ahead The macro calendar picks up next week. On 8 September, the US NFIB small-business optimism index is due. The 10th brings a heavier slate: initial jobless claims, final-demand PPI and its core reading, existing-home sales, wholesale sales, a 10-year Treasury auction, and EIA natural gas storage data. These prints will set the broader risk backdrop, though their direct link to Natera’s fundamentals is limited. On the company side, no earnings or major event is currently scheduled. What matters next is whether the quiet, low-volume drift continues and whether the Signatera lymphoma MRD validation generates any follow-through. ## In Short Natera closed a quiet week slightly higher, outperforming the S&P 500 while trading near the top of its weekly range. The fundamental input was the Signatera lymphoma MRD validation, set against a small CEO share sale. The rating picture is supportive: 19 of 22 covering institutions rate the stock buy or overweight, and the consensus target sits about 3% above spot, though the wide target range signals real disagreement. On the latest trading day, large-lot flow leaned net buying, but small-lot buying was proportionally larger, so positioning looks broad rather than concentrated. The open question is whether volume returns after this consolidation and whether the remaining upside to the consensus target narrows as price presses toward the upper end of the analyst range. *This article is generated by LongbridgeAI from market data, for information only and not investment advice.* ### Related Stocks - [NTRA.US](https://longbridge.com/en/quote/NTRA.US.md) ## Related News & Research - [Natera Executive Chairman Matthew Rabinowitz disposes of 89,100 common shares worth $30.15 million](https://longbridge.com/en/news/299253573.md) - [This Surprising Stock Has Been Stanley Druckenmiller's No. 1 Position for 8 Straight Quarters. Is It a No-Brainer Buy?](https://longbridge.com/en/news/298931347.md) - [Natera Executive Chairman Matthew Rabinowitz disposes of USD 16.32 million in common shares](https://longbridge.com/en/news/298779852.md) - [Billionaire Stanley Druckenmiller Has Roughly 17% of His $5.2 Billion Duquesne Portfolio in Natera Stock. Is It Still a Buy After an 80% Run?](https://longbridge.com/en/news/297400181.md) - [The Bull Case For Natera (NTRA) Could Change Following New Signatera Lymphoma Data And Komen Partnership](https://longbridge.com/en/news/298111249.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**